View printer-friendly version

Download PDF

Emergent BioSolutions Announces Acceptance of TRU-016 and TRU-Adhance Abstracts for Presentation at American Society of Hematology Meeting

ROCKVILLE, Md., Nov 09, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the acceptance of four abstracts for presentation at the 52^nd Annual Meeting of the American Society of Hematology (ASH) to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia (CLL). TRU-016 is Emergent’s humanized anti-CD37 small modular immunopharmaceutical (SMIP(TM)) protein in development for the treatment of B-cell malignancies such as CLL and non-Hodgkin’s lymphoma (NHL).

“Emergent is pleased with the Phase I data and tolerability profile of TRU-016 that will be presented at ASH,” said Dr. W. James Jackson, chief scientific officer at Emergent BioSolutions. “The fact that many patients with CLL experience disease relapse tells us that there is an acute need for differentiated treatments. We are encouraged by the clinical results and look forward to the next phase in our clinical development program for TRU-016.”

#56 Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIPTM Protein In Relapsed and Refractory CLL

Oral Session: CLL – Therapy, excluding Transplantation: Novel Agents and New Approaches

Sunday, December 5, 2010, 4:45 PM

Valencia D (Orange County Convention Center)

#3931 TRU-016, An Anti-CD37 SMIPTM Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin’s Lymphoma

Poster Session: Lymphoma – Pre-Clinical – Chemotherapy and Biologic Agents: Poster II

Monday, December 6, 2010, 6:00 PM-8:00 PM

Hall A3/A4 (Orange County Convention Center)

Poster Board III-710

#3098 CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma

Poster Session: Non-Hodgkin Lymphoma – Biology, excluding Therapy: Poster II

Sunday, December 5, 2010, 6:00 PM-8:00 PM

Hall A3/A4 (Orange County Convention Center)

Poster Board II-978

#1847 GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density

Poster Session: Molecular Pharmacology, Drug Resistance: Poster I

Saturday, December 4, 2010, 5:30 PM-7:30 PM

Hall A3/A4 (Orange County Convention Center)

Poster Board I-827

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed and investigational products target infectious diseases, oncology, and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2010, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including the success of our ongoing and planned preclinical studies and clinical trials; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: Emergent BioSolutions Inc.